RE:The receipt of a Rare Pediadiatric Disease Priority Review They had 4050/Fezagepras and Ryplazim potential last year. Interesting that they sold off Ryplazim/plasma/division for nothing except a voucher (no royalties, no milestone payments) and immediately stopped Phase 2 trials for their 2 most important indications that they took years to select out of all trials to move forward. The next shoe to drop in taking this provate will be announcing that they have found no indications that have shown "enough" PK action with larger doses to move forward. But the safety will be confirmed for those companies watching on the side lines.
Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras
MAY 28, 2021 SHRINAL INAMDARMay 28, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced today that based on interim pharmacokinetic (“PK”) results from the ongoing fezagepras multiple ascending dose (MAD) study, the Company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in Hypertriglyceridemia, as it evaluates the impact of the PK data profile observed in the on-going study.
The Company is continuing to evaluate the interim PK results. Once the MAD study is complete, the Company expects that a full analysis of the complete PK data set from the phase 1 study will help determine the choice of any other potential indication(s) for further development of fezagepras. No dose-limiting adverse events or other potential safety signals have been observed in the MAD study to date.Newcamo wrote: ... Voucher (PRV) also has the potential to provide Liminal with non-dilutive cash to support our ongoing efforts to advance and expand our small molecule R&D strategy.”
===>